107 related articles for article (PubMed ID: 24024697)
21. Regorafenib: start low and go slow.
Tabchi S; Ghosn M
Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
[No Abstract] [Full Text] [Related]
22. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
Yeh CN; Fu CJ; Yen TC; Chiang KC; Jan YY; Chen MF
J Clin Oncol; 2013 Jun; 31(16):e248-50. PubMed ID: 23569321
[No Abstract] [Full Text] [Related]
23. Does cetuximab cause small bowel perforation?
Ozturk MA; Eren OO; Oyan B
J BUON; 2014; 19(3):865. PubMed ID: 25261682
[No Abstract] [Full Text] [Related]
24. Eruptive nevi and hair depigmentation related to regorafenib.
Sibaud V; Munsch C; Lamant L
Eur J Dermatol; 2015; 25(1):85-6. PubMed ID: 25514168
[No Abstract] [Full Text] [Related]
25. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
26. Metastatic gastrointestinal stromal tumor and hypercalcemia in a patient with ulcerative colitis.
Al-Moundhri MS; Al-Thahli K; Al-Kindy S; Salam J; Rao L
Saudi Med J; 2006 Oct; 27(10):1585-7. PubMed ID: 17013488
[TBL] [Abstract][Full Text] [Related]
27. [A case of extragastric pedunculated gastrointestinal stromal tumor of the stomach with peritoneal dissemination].
Kikuchi A; Liu B; Chikatani K; Nishida K; Kawashima H; Miyamoto H; Kakimoto M; Goto H; Yoshimura T; Koshiishi H; Okamura T
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2387-9. PubMed ID: 23268086
[TBL] [Abstract][Full Text] [Related]
28. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.
Farooqi B; Simmons J; Hao Z
J Gastrointest Cancer; 2015 Sep; 46(3):314-6. PubMed ID: 25859838
[No Abstract] [Full Text] [Related]
29. Clinical Activity of Sunitinib and Regorafenib in Endometriosis.
Mir O; Ropert S; Morice P; Berveiller P
Mayo Clin Proc; 2019 Dec; 94(12):2591-2593. PubMed ID: 31806110
[No Abstract] [Full Text] [Related]
30. Fatal abdominal sarcomatosis secondary to gastrointestinal stromal tumor with bland histology.
Elshenawy YM; Ganote CE; Al-Abbadi MA
Saudi Med J; 2009 Nov; 30(11):1469-72. PubMed ID: 19882063
[TBL] [Abstract][Full Text] [Related]
31. [Cardiac toxicity of 5-fluorouracil].
Rexroth G; Scotland V
Med Klin (Munich); 1994 Dec; 89(12):680-8. PubMed ID: 7870005
[No Abstract] [Full Text] [Related]
32. Regorafenib: Dress.
Prescrire Int; 2015 Jan; 24(156):20-1. PubMed ID: 25729832
[No Abstract] [Full Text] [Related]
33. [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].
Yamanaka H; Mizushima T; Mikata S; Ito T; Nonaka K; Ide H; Michiura T; Kainuma S; Iwase K
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2125-8. PubMed ID: 16352942
[TBL] [Abstract][Full Text] [Related]
34. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
35. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
36. Hand-Foot Skin Reaction to Regorafenib.
Espinosa Lara P; Bueno Muiño C; Doger de Spéville B; Jiménez Reyes J
Actas Dermosifiliogr; 2016; 107(1):71-3. PubMed ID: 26232309
[No Abstract] [Full Text] [Related]
37. Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer.
Raissouni S; Quraishi Z; Al-Ghamdi M; Monzon J; Tang P; Vickers MM
BMC Res Notes; 2015 Oct; 8():538. PubMed ID: 26438070
[TBL] [Abstract][Full Text] [Related]
38. [Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate].
Sakakura C; Kumano T; Mizuta Y; Yamaoka N; Sagara Y; Hagiwara A; Otsuji E
Gan To Kagaku Ryoho; 2007 Nov; 34(12):2144-6. PubMed ID: 18219926
[TBL] [Abstract][Full Text] [Related]
39. A closer look at regorafenib.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2018 Oct; 16(10):667-669. PubMed ID: 30543596
[No Abstract] [Full Text] [Related]
40. Comment on: "Regorafenib: Start Low and Go Slow".
de la Fouchardière C
Target Oncol; 2016 Feb; 11(1):123-5. PubMed ID: 26634250
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
